iitri publications and press mentions

Our team is proud to share the promising news from multiple sponsors of recent IITRI in vivo studies. Links below to recent publications. Congrats all!   New Sponsor Publication from Mouse Influenza Studies at IITRI: Intranasal administration of a panreactive...

Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines Published Nov 19, 2024.Intranasal M2SR and BM2SR Vaccine Viruses Do Not Shed or Transmit in Ferrets Published Oct 29, 2024.Identification of CDK4/6...

 IITRI is proud to share recent accomplishments from two of our technical divisions. Several members of our Microbiology and Molecular Biology Division authored a recent publication entitled "Characterization of Three Variants of SARS-CoV-2 In Vivo Shows...

IITRI is happy to share the promising news of one of our Sponsors, Ascletis Pharma, Inc. They just announced the Investigational New Drug (IND) application of ASC10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus, has been filed with...

    IITRI is happy to share the good news from our collaboration with the National Cancer Institute (NCI) on their program focusing on an inhaled drug against SARS-CoV-2. Our team here at IITRI was contracted to perform toxicology studies for their drug...

IITRI is happy to share the promising news of one of our Sponsors, Ascletis Pharma, Inc. Our team here at IITRI was contracted to perform in vitro testing of their drug candidates for antiviral effects against multiple strains of SARS-CoV-2 as well as cytotoxicity....

  IITRI is proud to share the promising news from multiple sponsors of COVID-19 in vitro and in vivo studies. Links below to press releases and recent publications. Congrats all!   New IITRI Co-Author Publication: Scalable live-attenuated SARS-CoV-2 vaccine...

IITRI is proud to share the promising news of one of our partners, Moleculin!  Our team here at IITRI was contracted to perform additional in vitro testing of their drug candidate (WP1122) for antiviral effects against SARS-CoV-2. We used growth medium that more...

IITRI announces the recent award of three major new programs by the Biomedical Advanced Research and Development Authority (BARDA) valued at more than $4.7 M. The programs are for the development and/or evaluation of cutting edge technologies and agents to control...